MARATTO

article · Annals of Saudi Medicine

Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients

2024Open accessZagazig University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

The usual limitations of a retrospective analysis using registry-level data, no data on quality of life.

Research topics

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Cancer Mechanisms and Therapy

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher siteRecord on OpenAlex

DOI: 10.5144/0256-4947.2024.93

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

Sign in to join the discussion

New to MARATTO™? Create a free account.